Jiangsu Kanion Pharmaceutical Co., Ltd. is a large traditional Chinese medicine industrial enterprise dedicated to the R&D, manufacturing and marketing of modern TCM, and also a key Hi-Tech enterprise of China, a national technological innovation demonstration enterprise and one of top 100 enterprises in the Chinese pharmacy industry. The enterprise ranked the first place in “Ranking of TCM R&D Strength” for three consecutive years.
The company has established many state-level scientific research platforms such as National Key Laboratory for New Technologies in TCM Manufacturing Process, obtained 47 new state-level TCM and 427 invention patents successively, undertaken more than 50 science and technology projects, and won more than 10 state-level awards such as the second prize of National Scientific and Technological Progress Award and the second prize of National Technological Innovation. Its Guizhifuling capsule has completed phase II clinical trial in the United States and is striving to enter the European and American mainstream medicine market as a drug.
With adherence to high-quality development, the company has established a perfect product quality management system and constructed the first TCM intelligent manufacturing factory in the industry and realized the precision manufacturing of the whole Chinese patent medicine production process, i.e. “point consistency, segment consistency and batch consistency”. This project was listed as an intelligent manufacturing pilot project by the Ministry of Industry and Information Technology. The TCM intelligent solid preparation factory under construction responded to the planning of “Made in China 2015”. Its intelligent production level leads the TCM industry to show strong industry demonstration effect.
In the new era, the company will comprehensively plan the R&D strategic layout of “focusing on TCM and promoting biological medicine, chemical medicine and healthy products simultaneously”, accelerate the output and market transformation of new products, continuously maintain the dominant position in R&D, provide high-quality innovative medicine for clinic and write a new high-quality people-benefiting chapter in the TCM industry.